<DOC>
	<DOCNO>NCT01384162</DOCNO>
	<brief_summary>This open label safety tolerability continuation study intracerebroventricular administration sNN0029 , contain growth factor VEGF165 , patient amyotrophic lateral sclerosis previously participate study sNN0029-001 . The intention study investigate safety tolerability intracerebroventricular administration sNN0029 whether improve motor function prolong survival patient ALS .</brief_summary>
	<brief_title>An Open Label , Safety Tolerability Continuation Study Intracerebroventricular Administration sNN0029 Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Clinical diagnosis ALS classify definite , probable without additional laboratory evidence , accord revise WFN El Escorial criterion ( Appendix B ) . 2 . Previous participation study sNN0029001 completion 12 week study drug administration . 3 . To complete investigation associate safety study sNN0029001 without development clinically significant safety concern . 4 . Patient give write verbal information continuation study , opportunity ask question study , understands time procedural commitment . 5 . Patient give oral / sign consent ( write ) participate study . In event patient give oral informed consent physically able sign inform consent form ( ICF ) due disease progression , witness may sign ICF patient 's behalf . 1 . Hypertension define blood pressure &gt; 160 mmHg systolic &gt; 90 mmHg diastolic . 2 . Proliferative retinopathy . 3 . Nonproliferative retinopathy moderate severity high . 4 . Concurrent clinically significant dementia determine investigator . 5 . Concurrent clinically significant depression determine investigator . 6 . Need administration antiplatelet anticoagulant medication ( e.g . aspirin , Plavix , nonsteroidal antiinflammatory drug [ NSAIDs ] ) . Low dose aspirin occasional use NSAIDs allow ( See Appendix E ) . 7 . Clinically significant abnormality haematology clinical chemistry parameter assess investigator . 8 . For female patient , ongoing pregnancy plan pregnancy 9 . Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>VEGF165</keyword>
	<keyword>Safety</keyword>
	<keyword>Intracerebroventricular</keyword>
	<keyword>Infusion</keyword>
	<keyword>Implantable</keyword>
</DOC>